over several years, with $3 billion of the overall investment directed toward manufacturing expansion. Importantly, this does not represent incremental investment for BD, rather, a reprioritization of investments toward the U.S. to support domestic manufacturing and supply chain resiliency. The partnership also provides relief from future tariffs imposed under Section 232 ? on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD's achievement of agreed milestones. We've already mobilized the organization ? and begun taking action to deliver on these commitments. Turning to our new BD strategy, we're seeing clear progress against our three strategic pillars: compete, innovate, and deliver. Our growing commercial, innovation, and operational capabilities, our strengthening the quality of our growth, while improving earnings power and cash flow. Starting with compete, we've been raising the bar on commercial execution across BD, investing in every part of the commercial flywheel. That spans talent, AI sales tools, a disciplined sales process, and new pay-for-performance compensation plans, all powered by BD Excellence ? and a relentless focus on solving customer challenges with speed and urgency. In Q4, this translated into measurable outcomes across the company. Within connected care, commercial execution continued to drive share gains and new adoption across all platforms. In advanced patient monitoring, Salesforce investments are driving uptake of Hemosphere Ulta that contributed to strong capital growth in Q4. APM continues to perform well ahead of the deal model, generating one of its highest annual growth rates in the last 20 years, while significantly expanding margins under BD's ownership ? by applying BD excellence in APM manufacturing. Alaris finished the year with strong competitive momentum, gaining additional share in Q4 and more than 250 basis points for the full year. Dispensing also continued to gain share. With strong Pixis Pro order momentum and a 95% attachment rate of our new Encata AI platform. This strong early adoption reflects high customer interest in our new BD AI platform and supports our strategy to build recurring software, analytics, and AI revenue. In pharmacy automation, incremental investments we made coming into the year are delivering results. We're seeing increased central fill win rates and an improving growth outlook aided by the recent U.S. launch of BD VMAX. ? We exited the year with strong commercial momentum, winning all six central fill opportunities we competed for in Q4, with VMAX attached to every sale, reinforcing the strength of our portfolio in the growing U.S. healthcare system's central fill market. In biopharma systems, we expanded our position in next generation biologic drug delivery, including continued momentum in delivering GOP1 therapies. In interventional, incremental commercial investments are translating to stronger growth, with PI accelerating each quarter throughout the year. In UCC, Pure Wick delivered another quarter of double-digit growth, driven by continued adoption, competitive wins, and momentum in the VA channel. Across the portfolio, we're seeing our commercial investments translate into stronger growth and competitive performance. We've added resources in priority areas, introduced new tools, applied BD excellence to commercial execution, and better aligned incentives with our growth priorities. These actions are raising execution across new BD. Our second priority is innovate. We're concentrating investments in attractive markets where healthcare needs BD most and where we believe BD can create sustainable competitive advantage. ? This is in connected care, enabling the shift to newer low-cost settings, and advancing the treatment of chronic disease. Earlier this year, we moved more RD resources and decision making closer to the businesses. ? We increased investments behind our six key growth platforms, and our pipeline is expanding. We also deployed BD Excellence into RD this year and are introducing new products faster, having compressed launch times by an average of 10 months. In Q4, we received FDA approval for Liberty Tip STEMCraft, and we're seeing strong customer interest. ? In a market that's seen limited innovation for many years, Liberty brings enhanced ease of use, ? the broadest range of lengths, and compelling clinical data, broadening BD's presence in the approximately $2 billion global venous market, which is growing high single digits. ? We recently received 510K clearance for phasics ST peristomal, a first of its kind resorbable mesh designed specifically for peristomal hernial repairs. ? It's an underserved market with significant unmet clinical needs. ? With the launch expected in the first half of fiscal 27, this innovation further expands our advanced tissue regeneration portfolio and strengthens our position in the $1.8 billion served market. We're increasingly seeing the benefits of the strategic choices and investments we've made over the last several years. Combined with our strength and innovation capabilities and execution, we're building a robust pipeline ? and look forward to sharing more at our upcoming investor day next month. Our third priority, deliver, is about operational excellence at scale. ? It's about improving quality, service, productivity, margin, and cash flow. Through BD Excellence, we've built one of the most resilient supply chains in our industry, which combined with our scale, has become a meaningful competitive advantage. In fiscal twenty six, ? we delivered approximately 8% gross productivity in our plants with customer service levels above 90%. This was driven by more than 2,000 KIZAM events, resulting in higher manufacturing efficiencies and raw material savings, as well as ongoing network optimization. We are also generating value from the $200 million cost out program launched at the beginning of fiscal 26, with 100% of the savings now identified. Turning to capital allocation, ? our discipline framework remains unchanged. Importantly, we're seeing our operational progress translate into stronger cash generation. As free cash flow improves, so does our capacity to invest organically, return capital to shareholders, and pursue focused tuck-in MA. This will continue to increase as we drive towards our 90% free cash flow conversion target over time. In summary, fiscal 26 was an important year for BD. We completed our portfolio transformation to a pure play med tech company. We've strengthened execution and increasingly saw the benefits of the strategic choices and investments we've made over the last several years. Our differentiated growth platforms are strengthening our portfolio and expanding our opportunities for growth. We enter fiscal 27 with a more focused portfolio, and we have confidence in the underlying trajectory of new BD and our path towards sustainable mid-single-digit growth. Looking ahead, we see a compelling opportunity to combine that growth with continued earnings expansion and a step change in cash flow generation to drive long-term value creation. We are still early in realizing the full potential of new BD, ? and we look forward to laying out that opportunity in greater detail at our investor day on December 10th. With that, I'll turn it over to Vitor to provide more detail on our financial performance and guidance. Thanks, Tom, and good morning, everyone. We delivered a strong quarter with $5.3 billion ? in revenue up 5.6%. Excluding the Alaris prior year comparison, revenue growth was high single digits. As Tom highlighted, performance was broad-based, driven by continued double digit growth across multiple key platforms
Passages & reports (53) 4:06 over several years, with $3 billion of the overall investment directed toward manufacturin… Report 4:26 The partnership also provides relief from future tariffs imposed under Section 232 Report 4:32 on Report 4:32 covered BD products and inputs, subject to the final scope and implementation of any futur… Report 4:45 and Report 4:46 begun taking action to deliver on these commitments. Turning to our new BD strategy, we're… Report 5:06 growth, while improving earnings power and cash flow. Starting with compete, we've been ra… Report 5:25 pay-for-performance compensation plans, all powered by BD Excellence Report 5:30 and Report 5:30 a relentless focus on solving customer challenges with speed and urgency. In Q4, this tran… Report 5:50 Salesforce investments are driving uptake of Hemosphere Ulta that contributed to strong ca… Report 6:09 by Report 6:09 applying BD excellence in APM manufacturing. Alaris finished the year with strong competit… Report 6:29 a 95% attachment rate of our new Encata AI platform. This strong early adoption reflects h… Report 6:49 made coming into the year are delivering results. We're seeing increased central fill win … Report 7:00 We Report 7:01 exited the year with strong commercial momentum, winning all six central fill opportunitie… Report 7:21 in next generation biologic drug delivery, including continued momentum in delivering GOP1… Report 7:40 double-digit growth, driven by continued adoption, competitive wins, and momentum in the V… Report 7:59 BD excellence to commercial execution, and better aligned incentives with our growth prior… Report 8:19 sustainable competitive advantage. Report 8:22 This Report 8:22 is in connected care, enabling the shift to newer low-cost settings, and advancing the tre… Report 8:36 We Report 8:36 increased investments behind our six key growth platforms, and our pipeline is expanding. … Report 8:56 Liberty Tip STEMCraft, and we're seeing strong customer interest. Report 9:01 In Report 9:01 a market that's seen limited innovation for many years, Liberty brings enhanced ease of us… Report 9:06 the Report 9:07 broadest range of lengths, and compelling clinical data, broadening BD's presence in the a… Report 9:17 We Report 9:18 recently received 510K clearance for phasics ST peristomal, a first of its kind resorbable… Report 9:28 It's Report 9:28 an underserved market with significant unmet clinical needs. Report 9:32 With Report 9:32 the launch expected in the first half of fiscal 27, this innovation further expands our ad… Report 9:52 Combined with our strength and innovation capabilities and execution, we're building a rob… Report 9:58 and Report 9:58 look forward to sharing more at our upcoming investor day next month. Our third priority, … Report 10:07 It's Report 10:07 about improving quality, service, productivity, margin, and cash flow. Through BD Excellen… Report 10:23 we Report 10:23 delivered approximately 8% gross productivity in our plants with customer service levels a… Report 10:43 generating value from the $200 million cost out program launched at the beginning of fisca… Report 10:55 our Report 10:55 discipline framework remains unchanged. Importantly, we're seeing our operational progress… Report 11:15 our 90% free cash flow conversion target over time. In summary, fiscal 26 was an important… Report 11:35 made over the last several years. Our differentiated growth platforms are strengthening ou… Report 11:55 growth. Looking ahead, we see a compelling opportunity to combine that growth with continu… Report 12:12 and Report 12:12 we look forward to laying out that opportunity in greater detail at our investor day on De… Report 12:32 in Report 12:32 revenue up 5.6%. Excluding the Alaris prior year comparison, revenue growth was high singl… Report